Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 9/20 | 0.52 |
| ▸ | MMP2 | P08253 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 3/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6731740 | 0.88 | RAB9A (0.41) | NPC1PKMEPHX2RAB9ASMN1; SMN2 | |
| SCHEMBL6732073 | 0.86 | RAB9A (0.46) | MMP9MMP2NPC1PKMEPHX2 | |
| SCHEMBL6266744 | 0.78 | MMP8 (0.54) | MMP9MMP2MMP13MMP8MMP12 | |
| SCHEMBL6266747 | 0.78 | MMP8 (0.54) | MMP9MMP2MMP13MMP8MMP12 | |
| SCHEMBL6802716 | 0.74 | MMP13 (0.57) | MMP9MMP2RAB9AMMP13MMP8 | |
| SCHEMBL6271220 | 0.74 | MMP13 (0.57) | MMP9MMP2RAB9AMMP13MMP8 | |
| SCHEMBL8524291 | 0.71 | MMP9 (0.68) | MMP9MMP2RAB9AADAM17MMP13 | |
| SCHEMBL6341761 | 0.69 | TEAD1 (0.57) | MMP9MMP2NPC1RAB9AADAM17 | |
| SCHEMBL6341760 | 0.69 | TEAD1 (0.57) | MMP9MMP2NPC1RAB9AADAM17 | |
| SCHEMBL6341764 | 0.69 | TEAD1 (0.57) | MMP9MMP2NPC1RAB9AADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127717-A1 | Hydroxamic and carboxylic acid derivatives | MONTANA JOHN GARY (GB) | 2004-07-01 | — | — | US | claimed |
| US-20030236416-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 2003-12-25 | — | — | US | claimed |
| US-20040127717-A1 | Hydroxamic and carboxylic acid derivatives | MONTANA JOHN GARY (GB) | 2004-07-01 | — | — | US | disclosed |
| US-6680338-B2 | MATRIX METALLOPROTEINASE AND TUMOR NECROSIS FACTOR INHIBITORS; ANTICARCINOGENIC AGENTS; RHEUMATOID ARTHRITIS | DARWIN DISCOVERY LTD. (GB) | 2004-01-20 | — | — | US | disclosed |
| US-20030236416-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | DARWIN DISCOVERY LIMITED (GB) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236416-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES | HCAR1, HCAR2, HCAR3 | MMP9 631/4885MMP2 1221/4885NPC1 1544/4885 |
| US-20040127717-A1 | Hydroxamic and carboxylic acid derivatives | HCAR1, HCAR2, CBR1 | MMP9 833/4885MMP2 1582/4885NPC1 1330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.